Radio and PodcastRadio and PodcastLive Radio & Podcasts
Ep192: Kate Haviland on Following the Science to Precision Immunology artwork
Science & Medicine

Ep192: Kate Haviland on Following the Science to Precision Immunology

The Long Run with Luke Timmerman by The Long Run with Luke Timmerman

Jan 8, 202601:26:06Science & Medicine

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

About This Episode

Ep192: Kate Haviland on Following the Science to Precision Immunology is an episode from The Long Run with Luke Timmerman by The Long Run with Luke Timmerman. Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned...

Podcast

This episode belongs to The Long Run with Luke Timmerman.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jan 8, 2026, 01:26:06 long, audio available.

Related Episodes

Continue listening to more episodes from The Long Run with Luke Timmerman.